Skip to main content
  • Print publication year: 2009
  • Online publication date: May 2010

8 - Towards a pharmacology of depersonalization

Recommend this book

Email your librarian or administrator to recommend adding this book to your organisation's collection.

  • Online ISBN: 9780511730023
  • Book DOI:
Please enter your name
Please enter a valid email address
Who would you like to send this to *


Abel, K. M., Allin, M. P., Kucharska-Pietura, K. et al. (2003). Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. Neuroreport, 14, 387–391.
Abugova, M. A. (1996). Indices of pain threshold as a method of objective assessment of depersonalization therapy efficacy. Bekhterev Reviews in Psychiatry and Medical Psychology, 4, 120–122.
Akirav, I., Maroun, M. (2007).The role of the medial prefrontal cortex–amygdala circuit in stress effects on the extinction of fear. Neural Plasticity, 30873. Epub Jan 16.
Anand, A., Charney, D. S., Oren, D. A. et al. (2000). Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-d-aspartate receptor antagonists. Archives of General Psychiatry, 57, 270–276.
Baker, D., Hunter, E., Lawrence, E. et al. (2003). Depersonalisation disorder: clinical features of 204 cases. British Journal of Psychiatry, 182, 428–433.
Ball, S., Robinson, A., Shekhar, A., Walsh, K. (1997). Dissociative symptoms in panic disorder. Journal of Nervous and Mental Disease, 185, 755–760.
Ballon, J. S., Feifel, D. (2006). A systematic review of modafinil: potential clinical uses and mechanisms of action. The Journal of Clinical Psychiatry, 67, 554–566.
Bandura, A., Cioffi, D., Taylor, C.B, Brouillard, M. E. (1988). Perceived self-efficacy in coping with cognitive stressors and opioid activation. Journal of Personality and Social Psychology, 55, 479–488.
Bohus, M. J., Landwehrmeyer, G. B., Stiglmayr, C. E., Limberger, M. F., Böhme, R., Schmahl, C. G. (1999). Naltrexone in the treatment of dissociative symptoms in patients with borderline personality disorder: an open-label trial. The Journal of Clinical Psychiatry, 60, 598–603.
Bryant, R. A., Panasetis, P. (2005). The role of panic in acute dissociative reactions following trauma. British Journal of Clinical Psychology, 44, 489–494.
Cohen, M. R., Pickar, D., Dubois, M. (1983). The role of the endogenous opioid system in the human stress response. The Psychiatric Clinics of North America, 6, 457–471.
Chambers, R. A., Bremner, J. D., Moghaddam, B., Southwick, S. M., Charney, D. S., Krystal, J. H. (1999). Glutamate and post-traumatic stress disorder: toward a psychobiology of dissociation. Seminars in Clinical Neuropsychiatry, 4, 274–281.
Dager, S. R., Cowley, D. S., Dorsa, D. M., Dunner, D. L. (1989). Plasma beta-endorphin response to lactate infusion. Biological Psychiatry, 25, 243–245.
Davidson, J. R., Woodbury, M. A., Zisook, S., Giller, E. R. Jr. (1989). Classification of depression by grade of membership: a confirmation study. Psychological Medicine, 19, 987–998.
Eippert, F., Bingel, U., Schoell, E., Yacubian, J., Büchel, C. (2008). Blockade of endogenous opioid neurotransmission enhances acquisition of conditioned fear in humans. Journal of Neuroscience, 28, 5465–5472.
Eriksson, E., Westberg, P., Thuresson, K., Modigh, K., Ekman, R., Widerlöv, E. (1989). Increased cerebrospinal fluid of endorphin immunoreactivity in panic disorder. Neuropsychopharmacology, 2, 225–228.
Frew, A. K., Drummond, P. D. (2007). Negative affect, pain and sex: the role of endogenous opioids. Pain. 132, Suppl. 1, 577–85.
Glover, H. (1993). A preliminary trial of nalmefene for the treatment of emotional numbing in combat veterans with post-traumatic stress disorder. The Israel Journal of Psychiatry and Related Science, 30, 255–263.
Goodman, and Gilman, (2001). The Pharmacological Basis of Therapeutics, 10th edn. New York: McGraw Hill.
Griebel, G., Stemmelin, J., Scatton, B. (2005). Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biological Psychiatry, 57, 261–267.
Gutstein, H. B., Akil, H. (2006). Opioid analgesics. In Brunton, L. L., Lazo, J. S., Parker, K. L. (eds.) Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 11th edn. New York: McGraw-Hill, pp. 577–578.
Hill, M. N., Sun, J. C., Tse, M. T., Gorzalka, B. B. (2006). Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. The International Journal of Neuropsychopharmacology, 9, 277–286.
Hollander, E., Liebowitz, M. R., DeCaria, C., Fairbanks, J., Fallon, B., Klein, D. F. (1990). Treatment of depersonalization with serotonin reuptake blockers. The Journal of Clinical Psychopharmacology, 10, 200–203.
Hood, S. D., Hince, D. A., Robinson, H. (2006). Serotonin regulation of the human stress response. Psychoneuroendocrinology, 31, 1087–1097.
Kennedy, S. E., Koeppe, R. A., Young, E. A., Zubieta, J.K. (2006). Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Archives of General Psychiatry, 63, 1199–1208.
Krystal, J. H., Karper, L. P., Seibyl, J. P. et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry, 51, 199–214.
Lambert, M. V., Senior, C., Phillips, M. L., David, A. S. (2000). Depersonalization in cyberspace. Journal of Nervous and Mental Disease, 188, 764–771.
Liberzon, I., Zubieta, J. K., Fig, L. M., Phan, K. L., Koeppe, R. A., Taylor, S. F. (2002). Mu-opioid receptors and limbic responses to aversive emotional stimuli. Proceedings of the National Academy of Sciences, USA, 99, 7084–7089.
Lubin, G., Weizman, A., Shmushkevitz, M., Valevski, A. (2002). Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study. Human Psychopharmacology, 17, 181–185.
Mathew, R. J., Wilson, W. H., Humphreys, D., Lowe, J. V., Weithe, K. E. (1993). Depersonalization after marijuana smoking. Biological Psychiatry, 33, 431–441.
Melges, F. T., Tinklenberg, J. R., Hollister, L. E., Gillespie, H. K. (1970). Temporal disintegration and depersonalization during marihuana intoxication. Archives of General Psychiatry, 23, 204–210.
Metcalf, M. D., Coop, A. (2005). Kappa opioid antagonists: past successes and future prospects. AAPS Journal, 7, 704–722.
Moroz, B. T., Nuller, I. L., Ustimova, I. N., Andreev, B. V. (1990). Study of pain sensitivity based on the indicators of electro-odontometry in patients with depersonalization and depressive disorders. Zhurnal Nevropatologii Psikhiatrii Imeni S S Korsakova, 90, 81–82.
Nakazi, M., Bauer, U., Nickel, T., Kathmann, M., Schlicker, E. (2000). Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn-Schmiedeberg’s Archives of Pharmacology, 361, 19–24.
Nixon, R. D., Bryant, R. A. (2003). Peritraumatic and persistent panic attacks in acute stress disorder. Behavior Research Therapy, 41, 1237–1242.
Nuller, Y. L. (1982). Depersonalisation – symptoms, meaning, therapy. Acta Psychiatrica Scandinavica, 66, 451–458.
Nuller, Y. L., Morozova, M. G., Kushnir, O. N., Hamper, N. (2001). Effect of naloxone therapy on depersonalization: a pilot study. Journal of Psychopharmacology, 15, 93–95.
Pfeiffer, A., Brantl, V., Herz, A., Emrich, H. M. (1986). Psychotomimesis mediated by kappa opiate receptors. Science, 233, 774–776.
Philipsen, A., Schmahl, C., Lieb, K. (2004). Naloxone in the treatment of acute dissociative states in female patients with borderline personality disorder. Pharmacopsychiatry, 37, 196–199.
Phillips, M. L., Medford, N., Senior, C. et al. (2001). Depersonalization disorder: thinking without feeling. Psychiatry Research: Neuroimaging, 108, 145–160.
Resnick, O., Krus, D. M., Raskin, M. (1964). LSD-25 in normal subjects treated with monoamine oxidase inhibitor. Life Sciences, 3, 1207–1214.
Röder, C. H., Michal, M., Overbeck, G., van de Ven, V. G., Linden, D. E. (2007). Pain response in depersonalization: a functional imaging study using hypnosis in healthy subjects. Psychotherapy and Psychosomatics, 76, 115–121.
Russo, E. B., Burnett, A., Hall, B., Parker, K. K. (2005). Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochemical Research, 30, 1037–1043.
Sachdev, P. (2002). Citalopram–clonazepam combination for primary depersonalization disorder: a case report. The Australian and New Zealand Journal of Psychiatry, 36, 424–425.
Sedman, G., Kenna, J. C. (1964). The occurrence of depersonalization phenomena under LSD. Psychiatria et Neurologia (Basel), 147, 129–137.
Sierra, M., Phillips, M. L., Lambert, M. V., Senior, C., David, A. S., Krystal, J. H. (2001). Lamotrigine in the treatment of depersonalization disorder. The Journal of Clinical Psychiatry, 62, 826–827.
Sierra, M., Phillips, M. L., Ivin, G., Krystal, J., David, A. S. (2003). A placebo-controlled, cross-over trial of lamotrigine in depersonalization disorder. Journal of Psychopharmacology, 17, 103–105.
Sierra, M., Baker, D., Medford, N., Lawrence, E., Patel, M., Phillips, M. L., David, A. S. (2006). Lamotrigine as an add-on treatment for depersonalization disorder: a retrospective study of 32 cases. Clinical Neuropharmacology, 29, 253–839.
Simeon, D., Abugel, J. (2006). Feeling Unreal: Depersonalization Disorder and the Loss of Self. Oxford: Oxford University Press.
Simeon, D., Knutelska, M. (2005). An open trial of naltrexone in the treatment of depersonalization disorder. Clinical Journal of Psychopharmacology, 25, 267–270.
Simeon, D., Hollander, E., Stein, D. J. et al. (1995). Induction of depersonalization by the serotonin agonist meta-chlorophenylpiperazine. Psychiatry Research, 58, 161–164.
Simeon, D., Stein, D. J., Hollander, E. (1998). Treatment of depersonalization disorder with clomipramine. Biological Psychiatry, 44, 302–303.
Simeon, D., Knutelska, M., Nelson, D., Guralnik, O. (2003). Feeling unreal: a depersonalization disorder update of 117 cases. The Journal of Clinical Psychiatry, 64, 990–997.
Simeon, D., Guralnik, O., Schmeidler, J., Knutelska, M. (2004). Fluoxetine therapy in depersonalisation disorder: randomised controlled trial. The British Journal of Psychiatry, 185, 31–36.
Stein, M. B., Uhde, T. W. (1989). Depersonalization disorder: effects of caffeine and response to pharmacotherapy. Biological Psychiatry, 26, 315–320.
Wittmann, M., Carter, O., Hasler, F. et al. (2007). Effects of psilocybin on time perception and temporal control of behaviour in humans. Journal of Psychopharmacology, 21, 50–64.
Younger, J. W., Lawler-Row, K. A., Moe, K. A., Kratz, A. L., Keenum, A. J. (2006). Effects of naltrexone on repressive coping and disclosure of emotional material: a test of the opioid–peptide hypothesis of repression and hypertension. Psychosomatic Medicine, 68, 734–741.
Walsh, S. L., Strain, E. C., Abreu, M. E., Bigelow, G. E. (2001). Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berlin), 157, 151–162.